Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study wants to find out if a drug called belantamab mafodotin (also known as Blenrep) can help stop multiple myeloma from coming back after patients have a special type of stem cell transplant. They will also check if the drug is safe to use after the transplant.
This study wants to find out if a drug called belantamab mafodotin (also known as Blenrep) can help stop multiple myeloma from coming back after patients have a special type of stem cell transplant. They will also check if the drug is safe to use after the transplant.
Third Opinion AI Generated Synopsis
Trial Summary
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after transplant will also be studied
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after transplant will also be studied
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
